IRIS
SANTORO, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.789
AS - Asia 6.120
EU - Europa 4.783
SA - Sud America 872
Continente sconosciuto - Info sul continente non disponibili 807
AF - Africa 165
OC - Oceania 4
Totale 43.540
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.264
SG - Singapore 3.157
IT - Italia 1.062
CN - Cina 926
BR - Brasile 683
RU - Federazione Russa 625
DE - Germania 595
HK - Hong Kong 512
SE - Svezia 410
BD - Bangladesh 405
VN - Vietnam 378
CA - Canada 352
IE - Irlanda 352
FI - Finlandia 337
UA - Ucraina 311
FR - Francia 291
GB - Regno Unito 243
PL - Polonia 242
KR - Corea 241
JP - Giappone 154
NL - Olanda 87
IN - India 66
MX - Messico 62
ID - Indonesia 61
AT - Austria 56
AR - Argentina 52
ZA - Sudafrica 46
IQ - Iraq 38
ES - Italia 37
EC - Ecuador 33
CO - Colombia 29
JM - Giamaica 28
BE - Belgio 27
TR - Turchia 24
PH - Filippine 23
PK - Pakistan 22
CZ - Repubblica Ceca 20
VE - Venezuela 20
CL - Cile 18
MA - Marocco 18
CR - Costa Rica 17
CM - Camerun 16
DZ - Algeria 16
HN - Honduras 15
LT - Lituania 13
JO - Giordania 12
KE - Kenya 12
SA - Arabia Saudita 12
CH - Svizzera 11
EG - Egitto 11
PY - Paraguay 11
RO - Romania 11
BG - Bulgaria 10
BO - Bolivia 10
EU - Europa 10
UZ - Uzbekistan 10
IL - Israele 9
IR - Iran 8
MY - Malesia 8
PE - Perù 8
TT - Trinidad e Tobago 8
AE - Emirati Arabi Uniti 7
DO - Repubblica Dominicana 7
NI - Nicaragua 7
PR - Porto Rico 7
UY - Uruguay 7
AO - Angola 6
EE - Estonia 6
GR - Grecia 6
NG - Nigeria 6
TH - Thailandia 6
AL - Albania 5
GH - Ghana 5
KZ - Kazakistan 5
NP - Nepal 5
PT - Portogallo 5
TN - Tunisia 5
TW - Taiwan 5
AZ - Azerbaigian 4
DK - Danimarca 4
ET - Etiopia 4
GT - Guatemala 4
HU - Ungheria 4
PA - Panama 4
SV - El Salvador 4
AM - Armenia 3
CI - Costa d'Avorio 3
CY - Cipro 3
GD - Grenada 3
KG - Kirghizistan 3
LB - Libano 3
MN - Mongolia 3
TZ - Tanzania 3
ZM - Zambia 3
AU - Australia 2
BS - Bahamas 2
LY - Libia 2
MD - Moldavia 2
MT - Malta 2
PS - Palestinian Territory 2
Totale 42.712
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.937
Wilmington 6.850
Houston 5.428
Singapore 1.730
Ashburn 1.082
Fairfield 891
San Jose 891
Chandler 551
Ann Arbor 508
Hong Kong 498
Council Bluffs 491
Seattle 397
Beijing 372
Dublin 320
Rome 318
Cambridge 306
Santa Clara 277
Jacksonville 256
New York 251
Los Angeles 239
Helsinki 237
Medford 230
Kraków 213
The Dalles 180
Dearborn 176
Dundas 164
Tokyo 136
Ho Chi Minh City 115
Buffalo 108
Lawrence 108
Moscow 108
Milan 99
Hanoi 97
Dallas 88
Munich 86
Lauterbourg 78
São Paulo 71
Denver 70
Orem 66
Nuremberg 63
Toronto 63
San Diego 62
Phoenix 54
Chicago 53
Zhengzhou 53
London 52
Menlo Park 49
Jakarta 45
Atlanta 41
Mülheim 41
North Bergen 40
Boardman 32
Lappeenranta 31
Montreal 31
Creede 30
Amsterdam 29
Frankfurt am Main 29
Naples 29
New Orleans 28
Columbus 26
Palermo 26
San Francisco 26
Chennai 25
Falls Church 25
Vienna 23
Warsaw 23
Colorado Springs 22
Johannesburg 21
Mexico City 21
Redondo Beach 21
Dong Ket 20
North Charleston 20
Stockholm 20
Turin 20
Bologna 19
Boston 19
Brooklyn 19
Brussels 19
Florence 18
Haiphong 18
Rio de Janeiro 18
Poplar 17
Guangzhou 16
Seoul 16
Baghdad 15
Belo Horizonte 15
Kingston 15
Nanjing 14
Querétaro 14
Brasília 13
Brno 13
Da Nang 13
Manchester 13
Norwalk 13
Shenyang 13
Bogotá 12
Miami 12
Mumbai 12
Palo Alto 12
Porto Alegre 12
Totale 32.607
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 606
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy 593
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 593
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 555
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 547
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 529
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 527
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 524
Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization 518
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 510
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 500
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 492
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 492
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 491
Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy 487
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 484
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 483
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 482
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 478
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 466
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon 461
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 458
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 457
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 457
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 456
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 455
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 454
Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy 452
Dynamics of NRTI resistance mutations during therapy interruption 450
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 449
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 440
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 436
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 434
Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy 433
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 433
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 431
Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study 429
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 427
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 427
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 426
Impact of pre-therapy viral load on virological response to modern first-line HAART 424
HIV-1 Genetic Variability and Clinical Implications 424
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 424
Temporal change in the use of genotypic resistance testing over the years 1999--2003 423
Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines 422
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 421
Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon 419
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 415
Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir 412
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children 412
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 410
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 408
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 407
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen 405
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing 401
Clinical relevance of genotypic resistance testing today 399
HIV-1 non-B subtypes in Italy: a growing trend 394
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 394
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 387
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 382
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score 379
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 379
CEDRIC-HIV: la checklist per gli studi sulla resistenza ai farmaci anti-HIV 372
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 372
Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients 366
Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence 364
The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro 339
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 332
Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success 320
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment 318
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 315
Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy 288
HIV MDR is still a relevant issue despite its dramatic drop over the years 262
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T) 239
Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir 235
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 231
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses 231
Is the rate of virological failure to cART continuing to decline in recent calendar years? 224
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study 220
Genetic diversity of HIV type 1 in Montenegro 217
HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon 202
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 197
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients 187
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 186
Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat" 185
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 171
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 170
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 157
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 151
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 150
Impact of analytical treatment interruption on burden and diversification of HIV peripheral reservoir: a pilot study 147
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 146
Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis 145
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration 145
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 139
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 135
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 129
Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 128
Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon 127
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study 126
Totale 36.531
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.645
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.645
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.130 0 0 0 49 59 91 54 37 346 129 57 308
2022/20231.684 170 137 87 178 159 348 113 168 137 37 102 48
2023/2024683 80 18 29 24 53 126 37 18 19 138 11 130
2024/20254.735 160 906 460 241 141 254 599 193 418 293 539 531
2025/20268.240 574 315 671 730 870 361 1.029 951 833 797 586 523
2026/20272.605 430 396 1.255 524 0 0 0 0 0 0 0 0
Totale 43.540